Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...
Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback